BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1131 related articles for article (PubMed ID: 25499150)

  • 1. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
    Gill H; Leung AY; Kwong YL
    Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
    Itzykson R; Kosmider O; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
    Larsson CA; Cote G; Quintás-Cardama A
    Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic abnormalities and pathophysiology of MDS.
    Hosono N
    Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics factors associated with myelodysplastic syndromes.
    Macedo LC; Silvestre AP; Rodrigues C; de Alencar JB; Zacarias JM; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Blood Cells Mol Dis; 2015 Jun; 55(1):76-81. PubMed ID: 25976472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic syndromes: Contemporary review and how we treat.
    Gangat N; Patnaik MM; Tefferi A
    Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
    Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic basis of myelodysplasia and its clinical relevance.
    Cazzola M; Della Porta MG; Malcovati L
    Blood; 2013 Dec; 122(25):4021-34. PubMed ID: 24136165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome.
    Badaat I; Mirza S; Padron E; Sallman D; Komrokji R; Song J; Hussaini MO
    J Clin Pathol; 2020 Apr; 73(4):209-212. PubMed ID: 31771970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.
    Zahid MF; Patnaik MM; Gangat N; Hashmi SK; Rizzieri DA
    Eur J Haematol; 2016 Oct; 97(4):313-20. PubMed ID: 27147278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
    Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
    BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
    Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
    Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and genetic features of myelodysplastic syndromes.
    Greenberg PL
    Int J Lab Hematol; 2012 Jun; 34(3):215-22. PubMed ID: 22212119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What biologic factors predict for transformation to AML?
    Bejar R
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):341-345. PubMed ID: 30466744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.
    Harada H; Harada Y
    Cancer Sci; 2015 Apr; 106(4):329-36. PubMed ID: 25611784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.
    Bravo GM; Lee E; Merchan B; Kantarjian HM; García-Manero G
    Br J Haematol; 2014 Sep; 166(5):646-59. PubMed ID: 24903747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.